A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

NCT07700056 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Pruritus of Unknown Origin

Interventions

DRUG: Remibrutinib
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals